The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Mersana; MSD; Roche; Sotio; Stryker; Zai Lab
Research Funding - Boehringer Ingelheim (Inst); Genmab (Inst); Medac (Inst)
68Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.
 
Wolfgang P. Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; Janssen
Speakers' Bureau - Bayer; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Timo Bartel
No Relationships to Disclose
 
Kim M. Pabst
Research Funding - Bayer (Inst)
 
Rainer Hamacher
Honoraria - PharmaMar
Consulting or Advisory Role - PharmaMar
Speakers' Bureau - Lilly
Research Funding - Deutsche Forschungsgemeinschaft
Travel, Accommodations, Expenses - Lilly; Novartis; PharmaMar
 
Nader Hirmas
No Relationships to Disclose
 
Robert Seifert
No Relationships to Disclose
 
Stefan Kasper
Employment - University Hospital Essen (I)
Honoraria - Amgen; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Incyte; Janssen-Cilag; Lilly; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; BMS; Lilly; Merck Serono; Pierre Fabre; Roche; Sanofi
Other Relationship - Amgen; Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Sanofi
 
Michael Nader
No Relationships to Disclose
 
Claudia Kesch
Consulting or Advisory Role - Apogepha
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Curie Therapeutics (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development
 
Bastian von Tresckow
Honoraria - AstraZeneca; BMS; Incyte; MSD; Novartis; Roche; Roche Pharma AG; Takeda
Consulting or Advisory Role - Alimera Sciences; Amgen; Bristol-Myers Squibb/Celgene; Cerus; Incyte; IQVIA; Kite/Gilead; Miltenyi Biotec; MSD; Novartis; Pentixapharm; Pfizer; Roche; Takeda
Research Funding - MSD (Inst); Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AbbVie; AstraZeneca; Kite/Gilead; MSD; Novartis; Roche; Takeda
 
Christoph Berliner
Honoraria - ABX Advanced biochemical compounds
 
Sherko Kuemmel
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; Seagen; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Roche
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Philipp Harter
No Relationships to Disclose
 
Anke C. Reinacher-Schick
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; MCI Group; Merck Serono; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche
Research Funding - AIO-Studien (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); AstraZeneca (Inst); BioNTech (Inst); Celgene (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Lilly (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; Pierre Fabre; Pierre Fabre; Roche
 
Celine Lugnier
No Relationships to Disclose
 
Waldemar Uhl
No Relationships to Disclose
 
Boris A. Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Amgen; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; Janssen
 
Jens T. Siveke
Leadership - Pharma15
Stock and Other Ownership Interests - Pharma15
Consulting or Advisory Role - AstraZeneca; AstraZeneca (Inst); Bayer; Celgene; Immunocore; MSD; Novartis; Roche; SERVIER
Research Funding - Abalos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisbach Bio (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - SERVIER
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Onkowissen; PCI Biotech; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Serono; Pfizer
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - Aktis Oncology; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bain Capital; Bayer; BTG; GE Healthcare; IPSEN; ITG (Inst); Novartis; ROTOP Pharmaka (Inst); Siemens Healthineers